Abstract:Abstract Purpose This study aimed to profile the characteristics of patients with colorectal cancer (CRC) with a second primary malignancy (SPM) and to identify patients with CRC at high risk of developing SPMs. Methods We retrospectively reviewed data on patients with CRC aged 20–79 years from the Surveillance, Epidemiology, and End Results (SEER) database. Eligible patients were categorized into only one primary malignancy and SPM cohorts. A competing‐risk model was used to quantify associations between SPM occurrence and the multiple traits of patients. Finally, a decision curve analysis (DCA) was used to evaluate the clinical usefulness of the model by calculating net benefit. Results A total of 179,884 patients were identified, 18,285 (10.2%) of whom developed SPMs during a maximum follow‐up of approximately 18 years. The median survival time after the second diagnosis was less than 4 years. The 3‐year, 5‐year, and 10‐year cumulative risks of developing an SPM were 3.9%, 5.9%, and 10.0%, respectively. According to the multivariable competing‐risk model, male colon cancer survivors, older in age, with a well‐differentiated tumor and localized disease, who were treated with surgery were susceptible to SPMs. The DCA yielded a wide range of risk thresholds at which the net benefits would be obtained from our proposed model. Conclusion CRC survivors remain at high risk of developing SPMs. Patients with a second diagnosis of cancer showed not only significantly worse survival but also higher cancer‐specific mortality. A web‐based individualized predictive tool was also provided to assist clinicians in identifying patients at high risk of developing SPMs and planning their future care management. Implications for Practice Colorectal cancer survivors remain at high risk of developing a second primary malignancy (SPM). This study aimed to profile the characteristics of patients with colorectal cancer with second primary malignancies and to further explore the risk factors related to the development of second primary malignancies, using a large population‐based cohort. A clinically useful competing‐risk nomogram was developed to predict the risk of SPMs based on individual clinical factors. According to the findings, older age, male sex, white or black race, localized disease, and treatment with surgery among patients with colon cancer were associated with an increased risk of developing an SPM. These findings and the proposed tool could be useful to clinicians and caregivers in the clinical counseling of patients with colorectal cancer and the development of long‐term care management.

Continuing increased risk of second cancer in long‐term testicular cancer survivors after treatment in the cisplatin era

Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort

Risk of Second Primary Cancers among Long-Term Survivors of Breast Cancer

Radiation Therapy Changed the Second Malignancy Pattern in Rectal Cancer Survivors.

Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.

Radiotherapy of prostate cancer: impact of treatment characteristics on the incidence of second tumors

Excessive Risk of Second Primary Cancers in Young‐onset Colorectal Cancer Survivors

Comprehensive Genomic Profiling of 443 Patients with Advanced Renal Cell Carcinoma (rcc) to Reveal Clinically Relevant Genomic Alterations and to Aid in Classification of Rare Subtypes.

Risk of second cancers in long term survivors of neuroendocrine tumors of the large intestine.

Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort study

Risk of second primary thyroid cancer in cancer survivors

Radiotherapy and Increased Risk of Second Primary Cancers in Breast Cancer Survivors: an Epidemiological and Large Cohort Study

Genetic risk of second malignant neoplasm after childhood cancer treatment: A systematic review

Multiple Subsequent Neoplasms in the Childhood Cancer Survivor Study (ccss) Cohort

Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis

Epigenetic age acceleration in U.S. testicular cancer survivors (TCS).

Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis

Retrospective study of cisplatin plus radiotherapy toxicities in locally advanced squamous cell carcinoma of the head and neck – ReCisTT study

Initial surveillance in men with marker negative clinical stage IIA non‐seminomatous germ cell tumours